143 related articles for article (PubMed ID: 11378378)
1. Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
Baxter AD; Bhogal R; Bird J; Keily JF; Manallack DT; Montana JG; Owen DA; Pitt WR; Watson RJ; Wills RE
Bioorg Med Chem Lett; 2001 Jun; 11(11):1465-8. PubMed ID: 11378378
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and activity of selective MMP inhibitors with an aryl backbone.
Barta TE; Becker DP; Bedell LJ; De Crescenzo GA; McDonald JJ; Munie GE; Rao S; Shieh HS; Stegeman R; Stevens AM; Villamil CI
Bioorg Med Chem Lett; 2000 Dec; 10(24):2815-7. PubMed ID: 11133099
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
[TBL] [Abstract][Full Text] [Related]
4. The synthesis and biological activity of a novel series of diazepine MMP inhibitors.
Levin JI; DiJoseph JF; Killar LM; Sung A; Walter T; Sharr MA; Roth CE; Skotnicki JS; Albright JD
Bioorg Med Chem Lett; 1998 Oct; 8(19):2657-62. PubMed ID: 9873598
[TBL] [Abstract][Full Text] [Related]
5. alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
Becker DP; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Munie GE; Swearingen C
Bioorg Med Chem Lett; 2001 Oct; 11(20):2723-5. PubMed ID: 11591510
[TBL] [Abstract][Full Text] [Related]
6. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.
Michaelides MR; Dellaria JF; Gong J; Holms JH; Bouska JJ; Stacey J; Wada CK; Heyman HR; Curtin ML; Guo Y; Goodfellow CL; Elmore IB; Albert DH; Magoc TJ; Marcotte PA; Morgan DW; Davidsen SK
Bioorg Med Chem Lett; 2001 Jun; 11(12):1553-6. PubMed ID: 11412979
[TBL] [Abstract][Full Text] [Related]
7. [Antiangiogenic and antitumor effect of BPHA, an orally-active matrix metalloproteinase inhibitor, in in vivo murine and human tumor model].
Maki H; Maekawa R; Yoshida H; Hojo K; Uchida N; Wada T; Tanaka H; Takeda Y; Matsumoto M; Yamada H; Nishitani Y; Shono K; Kasai H; Sato S; Okamoto H; Hayashi R; Tamura Y; Tsuzuki H; Watanabe F; Sugita K; Yoshioka T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1599-606. PubMed ID: 10553417
[TBL] [Abstract][Full Text] [Related]
8. Molecular diversity of hydroxamic acids: part II. Potential therapeutic applications.
Lou B; Yang K
Mini Rev Med Chem; 2003 Sep; 3(6):609-20. PubMed ID: 12871163
[TBL] [Abstract][Full Text] [Related]
9. alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1.
Becker DP; Barta TE; Bedell L; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Mischke B; Munie GE; Swearingen C; Villamil CI
Bioorg Med Chem Lett; 2001 Oct; 11(20):2719-22. PubMed ID: 11591509
[TBL] [Abstract][Full Text] [Related]
10. Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
Ma D; Wu W; Yang G; Li J; Li J; Ye Q
Bioorg Med Chem Lett; 2004 Jan; 14(1):47-50. PubMed ID: 14684295
[TBL] [Abstract][Full Text] [Related]
11. Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC).
Curtin ML; Garland RB; Heyman HR; Frey RR; Michaelides MR; Li J; Pease LJ; Glaser KB; Marcotte PA; Davidsen SK
Bioorg Med Chem Lett; 2002 Oct; 12(20):2919-23. PubMed ID: 12270175
[TBL] [Abstract][Full Text] [Related]
12. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.
Bailey S; Bolognese B; Faller A; Louis-Flamberg P; MacPherson DT; Mayer RJ; Marshall LA; Milner PH; Mistry J; Smith DG; Ward JG
Bioorg Med Chem Lett; 1999 Nov; 9(21):3165-70. PubMed ID: 10560745
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.
Becker DP; Villamil CI; Barta TE; Bedell LJ; Boehm TL; Decrescenzo GA; Freskos JN; Getman DP; Hockerman S; Heintz R; Howard SC; Li MH; McDonald JJ; Carron CP; Funckes-Shippy CL; Mehta PP; Munie GE; Swearingen CA
J Med Chem; 2005 Oct; 48(21):6713-30. PubMed ID: 16220987
[TBL] [Abstract][Full Text] [Related]
15. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
[TBL] [Abstract][Full Text] [Related]
16. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
[TBL] [Abstract][Full Text] [Related]
17. Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase.
Jeng AY; Chou M; Parker DT
Bioorg Med Chem Lett; 1998 Apr; 8(8):897-902. PubMed ID: 9871508
[TBL] [Abstract][Full Text] [Related]
18. Design, combinatorial chemical synthesis and in vitro characterization of novel urea based gelatinase inhibitors.
Zhang Y; Li D; Houtman JC; Witiak DT; Seltzer J; Bertics PJ; Lauhon CT
Bioorg Med Chem Lett; 1999 Oct; 9(19):2823-6. PubMed ID: 10522699
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).
Fray MJ; Dickinson RP
Bioorg Med Chem Lett; 2001 Feb; 11(4):571-4. PubMed ID: 11229774
[TBL] [Abstract][Full Text] [Related]
20. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
Holms J; Mast K; Marcotte P; Elmore I; Li J; Pease L; Glaser K; Morgan D; Michaelides M; Davidsen S
Bioorg Med Chem Lett; 2001 Nov; 11(22):2907-10. PubMed ID: 11677124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
